Standardized Comparison of Clinical, Cognitive, Genetic, Neuroimaging, and Fluid Biomarkers for Predicting 24-Month Progression from Mild Cognitive Impairment to Alzheimer's Disease

Identifying individuals with mild cognitive impairment (MCI) likely to progress to Alzheimer’s disease (AD) is important for patient management and clinical trial enrollment. Although cognitive assessments, genetics, neuroimaging, and fluid biomarkers are each associated with disease progression, their predictive value has not been systematically compared using an identical cohort and evaluation framework. This study compared the predictive discrimination of clinical, cognitive, genetic, imaging, and cerebrospinal fluid (CSF) biomarkers, individually and combined, for 24-month progression from